Found 8 matching trials
Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma PHASE1 The purpose of this study is to evaluate the safety and efficacy of Bendamu...
Show More Location
Weill Cornell Medical College
Learn More & Join Trial
Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma PHASE1 This Phase I/II study is designed to first identify doses of MLN9708 and be...
Show More Location
Froedtert Hospital and the Medical College of Wisconsin
Learn More & Join Trial
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis PHASE1 The goal of this clinical trial is to treat male and female participants wi...
Show More Location
University of Kansas Medical Center
Learn More & Join Trial
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia PHASE1 This study is designed to determine the recommended phase 2 dose (RP2D), an...
Show More Location
Banner MD Anderson Cancer Center
Learn More & Join Trial
Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma PHASE1 This is a clinical trial to evaluate the safety of combining CAR T-cell the...
Show More Location
Weill Cornell Medicine/NewYork-Presbyterian Hospital
Learn More & Join Trial
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL) PHASE2 The purpose of this study is to evaluate the safety and efficacy of NOX A12...
Show More Location
Medical University Innsbruck, Division of Hematology and Oncology
Learn More & Join Trial
The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma PHASE1 To explore the efficacy and safety of pomalidomide and bendamustine with de...
Show More Location
Sun Yat-sen University Cancer Center
Learn More & Join Trial
Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma PHASE1 Isatuximab targets and kills CD38-positive myeloma cells in manner similar ...
Show More Location
Washington University School of Medicine
Learn More & Join Trial